The Newer Fluoroquinolones

Medical Clinics of North America

Volumn 95, Issue 4, 2011, Pages 793-817

  Bolon, Maureen K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiinfective agents; Fluoroquinolones; Microbial drug resistance; Pharmacokinetics; Pharmacology; Therapeutic use

Indexed keywords

CHLOROQUINE; CINOXACIN; CIPROFLOXACIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; SPARFLOXACIN; TEMAFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPATHY; AUTOIMMUNE HEMOLYTIC ANEMIA; DEATH; DRUG ACTIVITY; DRUG CHOICE; DRUG RECALL; DRUG STRUCTURE; FEVER; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEMOLYSIS; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; JAUNDICE; KIDNEY FAILURE; LIVER FAILURE; LIVER TOXICITY; NONHUMAN; PHARMACODYNAMICS; PHOTOTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RIGOR; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

EID: 79958811025     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2011.03.006     Document Type: Review

References (93)

1. Andriole V.T. The quinolones: past, present, and future. Clin Infect Dis 2005, 41(Suppl 2):S113-S119.
2. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003, 51(Suppl 1):21-27.
3. Drugs@FDA page Available at:, Accessed April 18, 2011. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
4. Hawkey P.M. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother 2003, 51(Suppl 1):29-35.
5. Jacoby G.A. Mechanisms of resistance to quinolones. Clin Infect Dis 2005, 41(Suppl 2):S120-S126.
6. O'Donnell J.A., Gelone S.P. The newer fluoroquinolones. Infect Dis Clin North Am 2004, 18(3):691-716. x.
7. Mehlhorn A.J., Brown D.A. Safety concerns with fluoroquinolones. Ann Pharmacother 2007, 41(11):1859-1866.
8. Ball P. The quinolones: history and overview. The quinolones 2000, 1-33. Academic Press, San Diego (CA). 3rd edition. V.T. Andriole (Ed.).
9. Stahlman R., Lode H. Safety overview: toxicity, adverse effects, and drug interactions. The quinolones 2000, 397-453. Academic Press, San Diego (CA). 3rd edition. V.T. Andriole (Ed.).
10. Niki Y., Hashiguchi K., Okimoto N., et al. Quinolone antimicrobial agents and theophylline. Chest 1992, 101(3):881. [letter].
11. Carroll D.N., Carroll D.G. Interactions between warfarin and three commonly prescribed fluoroquinolones. Ann Pharmacother 2008, 42(5):680-685.
12. Barton T.D., Fishman N.O., Weiner M.G., et al. High rate of coadministration of di- or trivalent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infect Control Hosp Epidemiol 2005, 26(1):93-99.
13. Cohen K.A., Lautenbach E., Weiner M.G., et al. Coadministration of oral levofloxacin with agents that impair absorption: impact on antibiotic resistance. Infect Control Hosp Epidemiol 2008, 29(10):975-977.
14. Rybak M.J. Pharmacodynamics: relation to antimicrobial resistance. Am J Med 2006, 119(6 Suppl 1):S37-S44. [discussion: S62-70].
15. Forrest A., Nix D.E., Ballow C.H., et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993, 37(5):1073-1081.
16. Dalhoff A., Schmitz F.J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003, 22(4):203-221.
17. Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis 2005, 41(Suppl 2):S127-S135.
18. Ambrose P.G., Grasela D.M., Grasela T.H., et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001, 45(10):2793-2797.
19. Drusano G.L., Preston S.L., Fowler C., et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004, 189(9):1590-1597.
20. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998, 279(2):125-129.
21. Thomas J.K., Forrest A., Bhavnani S.M., et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998, 42(3):521-527.
22. Falagas M.E., Bliziotis I.A., Rafailidis P.I. Do high doses of quinolones decrease the emergence of antibacterial resistance? A systematic review of data from comparative clinical trials. J Infect 2007, 55(2):97-105.
23. DeRyke C.A., Kuti J.L., Nicolau D.P. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 2007, 27(3):333-342.
24. van Zanten A.R., Polderman K.H., van Geijlswijk I.M., et al. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008, 23(3):422-430.
25. Morgan-Linnell S.K., Becnel Boyd L., Steffen D., et al. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009, 53(1):235-241.
26. Oram M., Fisher L.M. 4-quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother 1991, 35(2):387-389.
27. Khodursky A.B., Zechiedrich E.L., Cozzarelli N.R. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci U S A 1995, 92(25):11801-11805.
28. Vila J., Ruiz J., Goni P., et al. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1996, 40(2):491-493.
29. Vila J., Ruiz J., Goni P., et al. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother 1997, 39(6):757-762.
30. Ferrero L., Cameron B., Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995, 39(7):1554-1558.
31. Pan X.S., Ambler J., Mehtar S., et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996, 40(10):2321-2326.
32. Scheld W.M. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003, 9(1):1-9.
33. Fukuda H., Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999, 43(2):410-412.
34. Pestova E., Millichap J.J., Noskin G.A., et al. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 2000, 45(5):583-590.
35. Pletz M.W., Shergill A.P., McGee L., et al. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2006, 50(4):1561-1563.
36. de Cueto M., Rodriguez J.M., Soriano M.J., et al. Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation. J Clin Microbiol 2008, 46(4):1558-1560.
37. Hakanen A., Kotilainen P., Jalava J., et al. Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 1999, 37(11):3572-3577.
38. Kaatz G.W., Seo S.M., Ruble C.A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993, 37(5):1086-1094.
39. Cohen S.P., Hooper D.C., Wolfson J.S., et al. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother 1988, 32(8):1187-1191.
40. Li X.Z., Livermore D.M., Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother 1994, 38(8):1732-1741.
41. Brenwald N.P., Gill M.J., Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998, 42(8):2032-2035.
42. Kriengkauykiat J., Porter E., Lomovskaya O., et al. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49(2):565-570.
43. Martinez-Martinez L., Pascual A., Jacoby G.A. Quinolone resistance from a transferable plasmid. Lancet 1998, 351(9105):797-799.
44. Poirel L., Cattoir V., Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem?. Clin Microbiol Infect 2008, 14(4):295-297.
45. Yamane K., Wachino J., Suzuki S., et al. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother 2007, 51(9):3354-3360.
46. National Nosocomial Infections Surveillance System National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004, 32(8):470-485.
47. Bozeman L., Burman W., Metchock B., et al. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005, 40(3):386-391.
48. Felmingham D., Canton R., Jenkins S.G. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007, 55(2):111-118.
49. Inoue M., Lee N.Y., Hong S.W., et al. Protekt 1999-2000: a multicentre study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong, Japan and South Korea. Int J Antimicrob Agents 2004, 23(1):44-51.
50. Ip M., Chau S.S., Chi F., et al. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005. Antimicrob Agents Chemother 2007, 51(6):2192-2194.
51. Jacobs E., Dalhoff A., Korfmann G. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV study). Int J Antimicrob Agents 2009, 33(1):52-57.
52. Johnson D.M., Stilwell M.G., Fritsche T.R., et al. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY antimicrobial surveillance program (1999-2003). Diagn Microbiol Infect Dis 2006, 56(1):69-74.
53. Jones R.N., Kirby J.T., Rhomberg P.R. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 2008, 61(2):203-213.
54. Lockhart S.R., Abramson M.A., Beekmann S.E., et al. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007, 45(10):3352-3359.
55. Rosenthal V.D., Maki D.G., Mehta A., et al. International nosocomial infection control consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008, 36(9):627-637.
56. Zhanel G.G., DeCorby M., Laing N., et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008, 52(4):1430-1437.
57. Ho P.L., Yung R.W., Tsang D.N., et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001, 48(5):659-665.
58. Gagliotti C., Nobilio L., Moro M.L. Emergence of ciprofloxacin resistance in Escherichia coli isolates from outpatient urine samples. Clin Microbiol Infect 2007, 13(3):328-331.
59. Kaye K.S., Kanafani Z.A., Dodds A.E., et al. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006, 50(6):2192-2196.
60. Ray G.T., Baxter R., DeLorenze G.N. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa. Clin Infect Dis 2005, 41(4):441-449.
61. Weber S.G., Gold H.S., Hooper D.C., et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003, 9(11):1415-1422.
62. LeBlanc L., Pepin J., Toulouse K., et al. Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis 2006, 12(9):1398-1405.
63. MacDougall C., Harpe S.E., Powell J.P., et al. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005, 11(8):1197-1204.
64. MacDougall C., Powell J.P., Johnson C.K., et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005, 41(4):435-440.
65. Labbe A.C., Poirier L., Maccannell D., et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the bi/nap1/027 strain. Antimicrob Agents Chemother 2008, 52(9):3180-3187.
66. Razavi B., Apisarnthanarak A., Mundy L.M. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection 2007, 35(5):300-307.
67. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41(9):1254-1260.
68. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353(23):2442-2449.
69. Gaynes R., Rimland D., Killum E., et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004, 38(5):640-645.
70. McFarland L.V., Clarridge J.E., Beneda H.W., et al. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis 2007, 45(9):1141-1151.
71. del Rio C., Hall G., Hook E.W., et al. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007, 56(14):332-336.
72. Owens R.C., Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005, 41(Suppl 2):S144-S157.
73. Iannini P., Mandell L., Patou G., et al. Cutaneous adverse events and gemifloxacin: observations from the clinical trial program. J Chemother 2006, 18(1):3-11.
74. Lipsky B.A., Baker C.A. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999, 28(2):352-364.
75. Tanne J.H. FDA adds " black box" warning label to fluoroquinolone antibiotics. BMJ 2008, 337:a816. [comment].
76. Cipro [label information October 2008]. Available at:, 19847s42, 19857s49, 20780s26, 21473s24lbl.pdf. Accessed November 14, 2008. http://www.fda.gov/cder/foi/label/2008/019537s68.
77. Factive [label information October 2008]. Available at:, Accessed November 14, 2008. http://www.fda.gov/cder/foi/label/2008/021158s012lbl.pdf.
78. Levaquin [label information October 2008]. Available at:, Accessed November 14, 2008. http://www.fda.gov/cder/foi/label/2008/021721s020_020635s57_020634s52_lbl.pdf.
79. Avelox [label information October 2008]. Available at:, 021277s034lbl.pdf. Accessed November 14, 2008. http://www.fda.gov/cder/foi/label/2008/021085s040.
80. Khaliq Y., Zhanel G.G. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003, 36(11):1404-1410.
81. Stahlmann R., Forster C., Shakibaei M., et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy. Antimicrob Agents Chemother 1995, 39(9):2013-2018.
82. Owens R.C., Nolin T.D. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006, 43(12):1603-1611.
83. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001, 21(12):1468-1472.
84. Dale K.M., Lertsburapa K., Kluger J., et al. Moxifloxacin and torsades de pointes. Ann Pharmacother 2007, 41(2):336-340.
85. Altin T., Ozcan O., Turhan S., et al. Torsades de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 2007, 23(11):907-908.
86. Park-Wyllie L.Y., Juurlink D.N., Kopp A., et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006, 354(13):1352-1361.
87. Blum M.D., Graham D.J., McCloskey C.A. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994, 18(6):946-950.
88. Ziganshina L.E., Squire S.B. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008, 1. CD004795.
89. Pedro-Botet L., Yu V.L. Legionella: macrolides or quinolones?. Clin Microbiol Infect 2006, 12(Suppl 3):25-30.
90. Cullen M., Steven N., Billingham L., et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005, 353(10):988-998.
91. Bucaneve G., Micozzi A., Menichetti F., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005, 353(10):977-987.
92. Imran H., Tleyjeh I.M., Arndt C.A., et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008, 27(1):53-63.
93. Fraser A., Gafter-Gvili A., Paul M., et al. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev 2006, 4. CD004785.